Lamivudine in children with human immunodeficiency virus infection: A phase I/II study

Journal of Infectious Diseases

Volumn 174, Issue 1, 1996, Pages 16-25

  Lewis, Linda L ^a   Venzon, David ^b   Church, Joseph ^b   Farley, Maureen ^b   Wheeler, Sarah ^b   Keller, Amy ^b   Rubin, Marc ^b   Yuen, Geoffrey ^b   Mueller, Brigitta ^b   Sloas, Melisse ^b   Wood, Lauren ^b   Balis, Frank ^b   Shearer, Gene M ^b   Brouwers, Pim ^b   Goldsmith, Jonathan ^b   Pizzo, Philip A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; CD8 ANTIGEN; LAMIVUDINE; VIRUS RNA;

ADOLESCENT; ANEMIA; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL ACTIVITY; ARTICLE; ATAXIA; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH;

EID: 19244362628     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.1.16     Document Type: Article

References (31)

1. Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988;319:889-96.
2. McKinney RE, Pizzo PA, Scott GB, et al. Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. J Pediatr 1990;116:640-7.
3. Butler KM, Husson RN, Balis FM, et al. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991;324:137-44.
4. Tudor-Williams G, StClair M, McKinney RE, et al. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 1992;339:15-9.
5. Blanche S, Calvez T, Rouzioux C, et al. Randomized study of two doses of didanosine in children infected with human immunodeficiency virus. J Pediatr 1993;122:966-73.
6. Soudeyns H, Yao XJ, Gao Q, et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991;35:1386-90.
7. Coates JAV, Cammack N, Jenkinson HJ, et al. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992; 36:202-5.
8. Coates JAV, Cammack N, Jenkinson HJ, et al. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992;36:733-9.
9. Sommadossi JP, Schinazi RF, Chu CK, Xie MY. Comparison of cytotoxicity of the (-)-and (+)-enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrow progenitor cells. Biochemic Pharmacol 1992;44:1921-5.
10. Hart GJ, Orr DC, Penn CR, et al. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother 1992;36:1688-94.
11. Rooke R, Tremblay M, Soudeyns H, et al. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 1989;3:411-5.
12. Lamivudine clinical investigators' brochure. Research Triangle Park, NC: Glaxo, 1994.
13. van Leeuwen R, Lange JMA, Hussey EK, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992;6:1471-5.
14. Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center. Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. Pediatr Infect Dis J 1993;12:513-22.
15. Brouwers P, Belman A, Epstein L. Central nervous system involvement: manifestations, evaluation, and pathogenesis. In: Pizzo PA, Wilfert CM, ed. Pediatric AIDS: the challenge of HIV infection in infants, children, and adolescents. 2nd ed. Baltimore: Williams & Wilkins, 1994:433-55.
16. Conrad AJ, Schmid P, Syndulko K, et al. Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurologic abnormalities. J Acquir Immune Defic Syndr 1995;10:425-35.
17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid-guanidium thiocyanate-phenol-chloroform extraction. Ann Biochem 1987;162:156-9.
18. Roilides E, Clerici M, DePalma L, Rubin M, Pizzo PA, Shearer GM. Helper T-cell responses in children infected with human immunodeficiency virus type 1. J Pediatr 1991;118:724-30.
19. Clerici M, Roilides E, Butler KM, et al. Changes in T-helper cell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity. Blood 1992;80:2196-202.
20. Harker A, Evans GL, Hawley AE, Morris DM. High-performance liquid chromatographic assay for 2′-deoxy-3′-thiacytidine in human serum. J Chromatogr 1994;657:227-32.
21. Clerici M, Landay AL, Kessler HA, et al. Reconstitution of long-term T helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients. J Infect Dis 1992;166:723-30.
22. McKinney RE, Maha MA, Connor EM, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. N Engl J Med 1991;324:1018-25.
23. Husson RN, Mueller BU, Farley M, et al. Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection. Pediatrics 1994;93:316-22.
24. Pluda JM, Cooley TP, Montaner JSG, et al. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995;171:1438-47.
25. Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989;110:279-85.
26. Balis FM, Pizzo PA, Butler KM, et al. Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis 1992;165:99-104.
27. Butler KM, Venzon D, Henry N, et al. Pancreatitis in human immunodeficiency virus-infected children receiving ddl. Pediatrics 1993;91:747-51.
28. 3 [abstract LB31]. In: Program and abstracts of the Second National Conference on Human Retroviruses and Related Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1995.
29. 3 [abstract LB32]. In: Program and abstracts of the Second National Conference on Human Retroviruses and Related Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1995.
30. 3 [abstract LB34]. In: Program and abstracts of the Second National Conference on Human Retroviruses and Related Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1995.
31. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-9.